Shukra Pharmaceuticals (524632) Q4 22/23 earnings summary

Executive summary

• FY23 revenue from operations reached ₹5,883.37 lakh vs ₹2,048.60 lakh; profit after tax was ₹440.65 lakh vs ₹75.07 lakh. Management described total business as tripling YoY.

• Growth strategy centers on exports, generic products, R&D, and a new Shukra Wellness business marketing mouth-dissolving strips.

Financial highlights

• Revenue from operations was ₹5,883.37 lakh vs ₹2,048.60 lakh; total income ₹6,003.04 lakh vs ₹2,056.70 lakh.

• PBITDA was ₹656.00 lakh vs ₹296.67 lakh; PBT ₹444.17 lakh vs ₹101.80 lakh; PAT ₹440.65 lakh vs ₹75.07 lakh.

• Basic and diluted EPS rose to ₹26.21 from ₹4.79; total comprehensive income was ₹439.71 lakh vs ₹75.07 lakh.

• Operating cash flow was ₹316.95 lakh vs ₹798.85 lakh; closing cash and equivalents increased to ₹397.31 lakh from ₹28.96 lakh.

Outlook and guidance

• Management expects improved performance and increased revenue in coming years, citing new growth initiatives and operational programs to optimize cost and delivery.

• Plant registrations covered 10 countries, with plans to add 10 more in FY24; new Shukra Wellness strips target Brazil, Russia, Latin America, Africa, and neighboring Asian markets.

• R&D is developing novel and generic formulations plus patentable platform technologies and processes for domestic and export markets.